Research Article
Serum Anti-CCNY Autoantibody Is an Independent Prognosis Indicator for Postoperative Patients with Early-Stage Nonsmall-Cell Lung Carcinoma
Table 2
Multivariate analysis of prognostic factors in patients with NSLCL.
| Covariate | Covariate subgroup | HR | 95% CI | |
| Age | ≤60 | 1.127 | 0.557–2.281 | 0.739 | 60 | Gender | Male | 1.705 | 0.353–8.241 | 0.323 | Female | Smoke | Yes | 0.189 | 0.013–2.713 | 0.220 | No | Smoke index | ≤400 | 0.485 | 0.219–1.072 | 0.740 | 400 | Tumor site | Right | 1.522 | 0.712–3.251 | 0.278 | Left | Pathology type | A | 0.565 | 0.236–1.352 | 0.200 | S | Differentiation | Poor | 0.616 | 0.304–1.248 | 0.179 | Moderate + well | Levels of CCNY antibody | Negative | 4.044 | 1.849–8.843 | 0.006 | Positive | T | T1 | 1.290 | 0.838–1.981 | 0.247 | T2, 3, 4 | N | N0 | 1.121 | 0.763–1.645 | 0.561 | N1, 2, 3 | M | M0 | 4.485 | 1.412–14.243 | 0.011 | M1 | Levels of CCNY antibody | Negative | 2.380 | 1.101–5.104 | 0.026 | Positive | M | M0 | 4.092 | 1.371–12.210 | 0.012 | M1 |
|
|
: value; RR: relative risk to relapse; CI: confidence interval. Define as the significant difference.
|